David OMalley, Director of Translational & Clinical Research Partnerships; Leader, Clinical Trial Innovation at Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute, shared on LinkedIn:
“How slow should we go? New from our team in Gynecologic Oncology: real world steroid tapering for severe immunotherapy toxicities in gynecologic cancers.
Across 73 steroid tapers for grade 3-4 irAEs:
NCCN discordant tapers required additional medications more often (81.5% vs 56.2%)
Tapers under 28 days required additional medications in 100% of cases vs 57.6% for tapers of 28 days or longer, with more steroid reinitiation
The takeaway: shorter and guideline discordant tapers were associated with greater treatment escalation and steroid reinitiation. Rushing the taper can mean more steroids, not fewer. These data support guideline concordant tapering.
Huge shout out to the amazing team at OSU Gyn Onc, led by Dr. Laura Chambers and our great Dr. Jessica Velasquez. Proud to work alongside such a talented group.”
Title: How slow should we go? Variation and outcomes of steroid tapering for immunotherapy-related toxicities in gynecologic cancer
Authors: Jessica Velasquez, Julia Chalif, Danielle Glassman, Anna Gonzalez, Reed O’Connor, Cassidy Abdeen, Floor J. Backes, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Paulina J. Haight, Christa I. Nagel, Robert Neff, David M. O’Malley, Laura M. Chambers
Read the full article.
You can also read: CheckMate-274: Are We Measuring Long-Term Immunotherapy Toxicity Adequately?
